Genprex, Inc.
GNPX · XNASCIK 1595248fmd_0G9RCB901JMYWT1YWKZZEN4HNGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 41 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | – | 0 | 0 | 0 | 0 | 0 | – |
| Realized investment gains (losses) | – | – | – | – | – | – | – | (0) | (0) | (0) |
| Research and development | 0 | 0 | 1 | 2 | 7 | 9 | 12 | 18 | 11 | 9 |
| Operating income | (4) | (3) | (12) | (11) | (18) | (21) | (24) | (31) | (21) | (16) |
| Interest expense | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Other non-operating income (expense) | 0 | (0) | (0) | – | – | – | – | – | – | – |
| Income tax expense | – | – | – | – | – | – | 0 | 0 | 0 | 0 |
| Net income | (4) | (3) | (12) | (11) | (18) | (21) | (24) | (31) | (21) | (16) |
| Net income to common shareholders | – | – | – | – | – | – | – | (31) | (21) | (16) |